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Development of a Lateral Flow Recombinase Polymerase Assay for the 1 
diagnosis of Schistosoma mansoni infections 2 
Highlights 3 
• A LF-RPA assay has been developed for S. mansoni 4 
• Reactions take 6 minutes and can work at 25°C 5 
• The assay can detect 10pg of DNA and 102 copies of DNA 6 
• Betaine can rectify false positives but may influence assay sensitivity 7 
• The low resource need and quick time to results may enable PON testing 8 
 9 
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Abstract 15 
Infection with Schistosoma mansoni causes intestinal schistosomiasis, a major health 16 
problem across Africa. The accurate diagnosis of intestinal schistosomiasis is vital to inform 17 
surveillance/control programs. Diagnosis mainly relies on microscopic detection of eggs in 18 
faecal samples but many factors affect sensitivity. Molecular diagnostics are sensitive and 19 
specific but application is limited as necessary infrastructure, financial resources and skilled 20 
personnel are often lacking in endemic settings. Recombinase Polymerase Amplification 21 
(RPA) is an isothermal DNA amplification/detection technology that is practical in nearly any 22 
setting. Here we developed a RPA lateral flow (LF) assay targeting the 28S rDNA region of S. 23 
mansoni. The 28S LF-RPA assay's lower limit of detection was 10pg DNA with the lower test 24 
parameters permitting sufficient amplification being 6 minutes and 25°C. Optimal assay 25 
parameters were 40-45°C and 10 mins with an analytical sensitivity of 102 copies of DNA. 26 
Additionally the PCRD3 lateral flow detection cassettes proved more robust and sensitive 27 
compared to the Milenia HybriDetect strips. This 28S LF-RPA assay produces quick 28 
reproducible results that are easy to interpret, require little infrastructure and is a promising 29 
PON test for the field molecular diagnosis of intestinal schistosomiasis. 30 
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 34 
1. Introduction 35 
 Schistosomiasis is a neglected tropical disease (NTD) second only to malaria in 36 
infection rates [1] with 230 million people estimated to be infected worldwide [2,3]. It is 37 
endemic in Africa, Asia, the Middle East and parts of South America, however the greatest 38 
burden of disease is found in sub-Saharan Africa where S. haematobium (causing urogenital 39 
schistosomiasis) and S. mansoni (causing intestinal schistosomiasis) cause 90% of global 40 
infections resulting in an estimated mortality rate of around 200,000 per year [4]. Infection 41 
occurs when larval stages of the parasite are shed from the specific fresh water snails and 42 
enter through the human skin via water contact. These larval forms mature in the liver and 43 
then migrate to either the mesenteric veins (S. mansoni) or to the perivesicular veins (S. 44 
haematobium) where adult worms exist as a reproductive pair and produce many 45 
thousands of eggs per day [2]. The World Health Organization (WHO) has targeted 46 
schistosomiasis for elimination as a public health problem (defined as reducing prevalence 47 
of heavy-intensity infection to below 1%) in all endemic countries with a halt in transmission 48 
in most of these countries by 2025 [5,6]. This is to be achieved principally through mass 49 
drug administration (MDA) of oral praziquantel (PZQ) to kill adult worms [5] but will also 50 
require sensitive diagnostics to be able to identify low intensity infections, and also to set 51 
effective treatment intervals. The current standard diagnostic test for S. mansoni infection 52 
involves taking a double smear of a single stool sample for microscopic detection of 53 
schistosome eggs [7,8]. This is not only time-consuming, but lacks sensitivity particularly in 54 
low-intensity infections [7-15], leading to an under-estimation of disease prevalence. It is 55 
probable therefore that many infections are being missed using current diagnostic methods, 56 
and elimination goals are unlikely to be achieved unless a more sensitive, quick, easy to 57 
perform and cost-effective method of detection is developed. 58 
 Molecular diagnostics and molecular technologies are rapidly advancing and offer 59 
greater sensitivities and specificities over existing disease diagnostics. For the detection and 60 
quantification of Schistosoma-specific DNA in clinical samples, a number of molecular 61 
techniques and range of molecular targets have been put into practice [16-18]. Polymerase 62 
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Chain Reaction (PCR) amplification of schistosome DNA within clinical samples has been 63 
shown to be highly sensitive in detecting S. mansoni, able to detect down to 2.4 eggs per 64 
gram of faeces [18]. An added advantage is the flexibility of using different types of sample 65 
due to the ability to detect not only eggs but also Cell-Free-Parasite-DNA (CFPD) in clinical 66 
samples. However, current molecular diagnostic use is hampered by the need for expensive 67 
laboratory equipment, highly skilled personnel and cold-chain storage devices, not readily 68 
available within most endemic countries [16]. Recombinase Polymerase Amplification (RPA) 69 
is a novel isothermal (requiring constant ambient temperatures) DNA amplification 70 
technology being developed for the Point-Of-Need (PON) diagnosis of several important 71 
pathogens including those causing NTDs [19-22]. The technology is sensitive and specific but 72 
also overcomes many of the obstacles faced by existing molecular diagnostics; being rapid, 73 
robust, high-throughput, requiring low energy and portable equipment, with results 74 
available using field-friendly detection devices, making this a promising technology for 75 
molecular PON diagnosis [19,20]. There are an increasing number of reports combining 76 
isothermal amplification with simple and rapid lateral flow detection of amplified DNA [20-77 
30), moving nearer to achieving molecular diagnostics that can be used at the PON. A 78 
Lateral Flow (LF) RPA assay for the detection of S. japonicum DNA targeting the highly 79 
repetitive retrotransposon SjR2 region in faecal samples has been shown to have equal 80 
sensitivity to both quantitative PCR and real time (RT) RPA, detecting 5fg S. japonicum DNA 81 
which is reportedly less than that found in one egg [21]. The assay also showed high 82 
specificity, showing no cross-reactivity with other helminthic parasites [21]. A previous LF-83 
RPA study targeting the tandem repeat Dra-1 sequence of S. haematobium found successful 84 
amplification and detection between assay temperatures of 30-45°C, in 10 minutes 85 
incubation time, and with a sensitivity of 100fg DNA [22]. There is no existing molecular PON 86 
diagnostic test for S. mansoni and so here we aimed to develop an RPA assay for the 87 
sensitive detection of S. mansoni DNA, and to test different reaction parameters for the 88 
assay’s suitability for the endemic PON setting. Two different nuclear DNA targets were 89 
evaluated for optimal assay design and performance and the results are discussed in 90 
relation to the assay’s potential for field PON testing on clinical samples.  91 
 92 
2. Materials and Methods 93 
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2.1 S. mansoni Genomic DNA 94 
S. mansoni (Ugandan Isolate, Lake Victoria) adult worm genomic DNA was obtained 95 
from the Schistosomiasis Collection at The Natural History Museum (SCAN) [31], and was 96 
quantified using the NanoDrop ND-8000 8-Sample Spectrophotometer.  97 
 98 
2.2 RPA primer design 99 
The S. mansoni 28S and ITS ribosomal DNA regions were targeted for amplification. 100 
Their sequences were downloaded from Genbank (NCBI) as these have been used in 101 
previous molecular diagnostic assays [16, 18] (https://www.ncbi.nlm.nih.gov/genbank/). 102 
Accession numbers; JQ289757 (ITS); AY157173.1 (28S). Multiple forward and reverse RPA 103 
primers were designed using Primer3 (http://primer3.ut.ee). RPA primers were designed 104 
following the TwistDxTM guidelines to be 30-35 bases long with 30-70% GC content for both 105 
regions. The primers were designed to produce the smallest possible amplicon to maximize 106 
amplification rates. A gap of at least 52bp was maintained between primer pairs to allow for 107 
internal probe design for lateral flow detection.  108 
 109 
2.3 ITS and 28S RPA primer screening 110 
Primers were screened using the TwistAmpTM Basic kit to determine the best primer 111 
pairs according to product yield using the TwistAmpTM Basic kit reagents. To prevent cross 112 
contamination, preparation of all RPA reactions was carried out in a pre-PCR room under 113 
extraction hoods, and all reagents were left under UV light before and after each batch of 114 
reactions was run. There were eight possible primer pairs to be tested; six ITS pair 115 
combinations covering a 267bp region, and two 28S primer pair combinations covering a 116 
327bp region. All primer screening was done using 1ng of S. mansoni genomic DNA.  117 
Reactions were set-up following the TwistDxTM Basic RPA protocol with each reaction 118 
containing 29.5µl rehydration buffer, 2.4µl of each forward and reverse primer (10pmol), 119 
12.2µl dH20, and 1µl of S. mansoni genomic DNA for each reaction mix. The RPA pellets 120 
were first decanted into 0.2ml PCR tubes for easier handling, the reaction mix was then 121 
added, vortexed and spun down. 2.5µl of magnesium acetate was added to each lid making 122 
a total reaction volume of 50µl and a magnetic bead was dispensed into each tube for 123 
magnetic mixing. Tubes were centrifuged and immediately placed into the TwirlaTM, a 124 
portable heat block with internal magnetic motor; the motor agitates the mix every 10 125 
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seconds preventing the need for a manual mixing step. Incubations were initially performed 126 
at 40°C for 20 minutes. Amplification products were purified using the QIAquick PCR 127 
Purification Kit (Qiagen, Germany), and run on a 4% gel red agarose gel (Sigma Aldrich, UK). 128 
Negative no DNA template controls were incorporated into each set of reactions. Primer 129 
pairs that gave strong positive amplification of the correct size amplicon with no non-130 
specific amplification were selected for further development. Additionally the primer pairs 131 
that gave the smaller size amplicons were selected to facilitate rapid amplification.  132 
 133 
2.4 Lateral flow RPA probe design and testing 134 
 Internal lateral flow RPA probes were designed for both the 28S and ITS DNA regions 135 
following the TwistDx guidelines, with lengths of between 46-52 nucleotides, containing 136 
either a 6-carboxyfluorescein (FAM) label or a biotin label at the 5’ end. A basic 137 
tetrahydrofuran (THF) residue replaced a single nucleotide at least 30bp from the 5’ end and 138 
at least 15 nucleotides from the 3’ end. A C3 spacer at the 3’ end prevents extension of any 139 
un-hybridised probe. To enable lateral flow detection, reverse primers were modified by 140 
attaching either a biotin recognition label or a FAM label to the 5’ end. If the probe was 141 
labelled with the FAM then the reverse primer was labeled with biotin and vice versa. The 142 
ITS and 28S LF-RPA reactions were performed using the TwistDx nfo kit. Reactions contained 143 
1ng of S. mansoni DNA, 29.5µl of rehydration buffer, 2.1µl forward primer (10pmol), 2.1µl 144 
labeled reverse primer (10pmol), 0.6µl of the specific internal lateral flow probe (10pmol), 145 
and 12.2μl dH20 for each reaction. These were mixed and added to the RPA nfo pellets. A 146 
magnetic bead was added for magnetic mixing and then 2.5µl of magnesium acetate was 147 
added to the lids before the reactions were closed, centrifuged and incubated in the Twirla 148 
for 20 minutes. Negative no DNA template controls were also included with each set of 149 
reactions performed. 150 
2.5 28S and ITS LF-RPA amplicon detection 151 
S. mansoni DNA amplification was detected using both the Milenia HybriDetect 152 
lateral flow dipsticks (Milenia Biotec GmbH, Gieβen, Germany) and also the PCRD Nucleic 153 
Acid Detector lateral flow assay cassettes (Abingdon Health, York, UK) for comparison. 154 
Detection occurs in a typical ‘sandwich’ format, with the target, in this case via the probe, 155 
forming a conjugate with recognition anti-FAM antibodies on the sample application area, 156 
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and is then captured at the test line by anti-biotin antibodies to form a complex with 157 
colloidal carbon (PCRD) or colloidal gold (Milenia), producing a coloured signal. A control 158 
line is also visualised on the test strips to prevent any false negatives through failure of the 159 
lateral flow strips.  160 
To prevent contamination by RPA amplicons post-amplification processing of the ITS 161 
and 28S RPA assays for lateral flow detection was carried out in a separate post-PCR area to 162 
the reaction set up and also under an extraction hood. For the PCRD strips 5µl of the RPA 163 
amplification product was added to 70µl PCRD running buffer. Then 75µl of this mix was 164 
pipetted into the sample well on the cassette. Results were read at no later than 10 165 
minutes. For Milenia HybriDetect strips 5µl of RPA amplification product was added to 166 
100µl HybriDetect buffer. The detection strip was placed vertically into the tube containing 167 
the mix with the sample application pad submerged in the solution. Results were read 168 
between 5-15 minutes. 169 
 170 
2.6 Addition of Betaine 171 
To address problems with false positive results with the ITS LF-RPA assays, the 172 
addition of Betaine to the RPA reactions was trialed with an aim to reduce primer noise and 173 
mis-priming. 1µl, 5µl and 7.5µl of Betaine (5M) were each substituted for the same amount 174 
of dH20 in the reaction mix in the ITS RPA reactions to maintain reaction volumes at 50µl. 175 
This was tested with negative no DNA template control reactions for each primer pair to 176 
determine the minimum Betaine concentration that would effectively prevent false positive 177 
results from occurring on the detection strips. This was not done for the 28S LF-RPA 178 
reactions as no false positives were encountered.  179 
2.7 LF-RPA Reaction parameter testing 180 
Different parameters were tested 10 times to assess accuracy. 181 
2.7.1 Temperature 182 
The LF-RPA assays were tested on template DNA (1ng) at different reaction temperatures; 183 
20, 25, 30, 35, 40, 45 and 50°C for 20 minutes. When using incubation temperature as the 184 
RPA assay variable, incubations were performed in a standard PCR machine (GeneAmp PCR 185 
System 9700) set at the required temperature. Reactions were manually mixed every 5 186 
minutes to prevent localised depletion of reagents caused by viscosity of the reaction mix 187 
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 188 
2.7.1 Reaction Time  189 
LF-RPA assays were tested on template DNA (1ng) with different reaction times to 190 
determine the minimum length of time needed for DNA amplification and detection. 191 
Reactions were run at 5, 6, 7, 8, 9, 10 and 15 minutes duration in the Twirla (40°C), and 192 
immediately halted by placing tubes on ice before further processing.  193 
 194 
2.8 Analytical Sensitivity and specificity 195 
2.8.1 Sensitivity  196 
Serial dilutions of the S. mansoni DNA were made by diluting the 1ng/µl stock DNA 197 
with water to give dilutions of 100pg /µl, 10pg/µl, 1pg/µl, and 100fg/µl of DNA. 198 
ITS and 28S LF-RPA reactions were tested on these DNA dilutions to determine the analytical 199 
sensitivity of these assays. All reactions were run in the Twirla device with magnetic mixing 200 
at 40°C for 20 minutes. 201 
 202 
2.8.2 Specificity  203 
The LF-RPA assays were tested on DNA from other important schistosome species found co-204 
endemically with S. mansoni. The ITS and 28S LF-RPA assays were tested using 1ng of S. 205 
haematobium and S. bovis DNA from the Schistosomiasis Collection at the NHM (SCAN) to 206 
determine cross reactivity of the LF-RPA assays. Other pathogens samples were not 207 
available for testing so the primers were Blasted against the NCBI Genbank database 208 
(https://blast.ncbi.nlm.nih.gov/Blast) to evaluate which other organisms they might also be 209 
compatible with.  210 
 211 
2.9 Analytical limit of detection 212 
As the 28S DNA region and primer probe combination proved the most robust with no 213 
issues with false positive reactions a DNA standard was created for the 28S DNA target to 214 
determine the analytical limit of detection of the 28S LF-RPA assay. A linearized molecular 215 
28S DNA standard was synthesized (GeneArt, Invitrogen, Darmstadt Germany) and diluted 216 
to give a measure of numbers of molecules per µl. The 28S LF-RPA assay was tested on 108, 217 
107, 106, 105, 104, 103, 102, 101 copies of the molecular DNA standard. All reactions were run 218 
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using the standard 28S LF-RPA protocol and the reactions were performed in the Twirla 219 
device with magnetic mixing at 40°C for 20 minutes. Amplicon detection was performed 220 
using the PCRD reaction strips as described previously. The limit of detection was tested 221 
multiple times to assess robustness of the assay.   222 
3. Results 223 
3.1 ITS and 28S RPA primers and probes 224 
Sequences for all ITS and 28S primers and probes are shown in Table 1, including reverse 225 
primer modifications for LF-RPA testing. 226 
 227 
Name Sequence (5’-3’) 
ITS 59 F ACCAGAGACAAGATCAAGTGATTAACGTAG 
ITS 65 F GACAAGATCAAGTGATTAACGTAGCATACG 
ITS 70 F GATCAAGTGATTAACGTAGCATACGATAGG 
ITS 192 R [Btn]CTAGTCTGGTCTAGATGACTTGATTGAGATG 
ITS 312 R [Btn]CTTTTCATCTATCACGACGCACATTAAGTC 
ITS probe 
[6FAM]TCCCGAGCGTGTATAATGTCATTAAGCCACGA[THF]TCGAGCACAACCCACCGC
A[SpcC3] 
28S 335 F GTTTGCTATCGGACTCGTGTAAGTATTTAG 
28S 353 F GTAAGTATTTAGCCTTGGATGGAGTTTACC 
28S 647 R [6FAM]AGAAACTAACAAGGATTCCCCTAGTAACTG 
28S probe 
[Btn]TAAACACCACATTGCCTTACGATCAAATAAC[THF]CGCAGGCTTTCGGTGTTGGGC
T[SpcC3] 
 228 
Table 1. ITS and 28S primer and probe sequences designed for the LF-RPA assays. 229 
Modification codes: Btn = Biotin label, 6FAM = FAM label, THF = basic tetrahydrofuran 230 
residue, SpcC3= C3Spacer.  231 
 232 
3.2 Primer pair screening 233 
All ITS and 28S primer combinations successfully amplified 1ng of S. mansoni DNA. Results 234 
visualised on a agarose gel confirmed the correct DNA amplicon lengths expected from each 235 
primer pair (Figure 1). Three ITS primer pairs (1. 70F + 192R (122bp*), 2. 65F + 192R 236 
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(127bp*), 3. 59F + 192R (133bp*) and one 28S primer pair (353F + 647R (294bp*)), were 237 
selected for further optimisation based on the smaller amplicon lengths produced and 238 
strong band signal intensity  (Figure 1). A shorter amplicon is more desirable as it will equate 239 
to a faster amplification rate and generates fewer primer ‘artefacts’, providing greater 240 
sensitivity [32].  241 
 242 
 243 
 244 
 245 
 246 
 247 
 
 
Figure 1. A) amplicons produced by the 6 ITS primer pair combinations. 1. 70F + 192R 250 
(122bp*), 2. 65F + 192R (127bp*), 3. 59F + 192R (133bp*), 4. 70F + 312R (242bp), 5. 65F +  251 
312R (247bp), 6. 59F + 312R (253bp)  B) amplicons produced by the 2 28S primer pair 252 
combinations. 1. 353F + 647R (294bp*), 2. 335F + 647R (312bp). The ladder in lane 1 is 253 
Hyperladder IV. *These primer pairs were chosen for further optimization and LF RPA 254 
development.  255 
3.3 Lateral Flow (LF) RPA development 256 
Due to the high cost of the internal LF probes only a single ITS and 28S probe were designed 257 
and tested.  258 
3.3.1 ITS LF-RPA assays 259 
The ITS LF-RPA reactions were hampered by false positive results with all the primer probe 260 
combinations tested. It was suspected that false positives might be caused by a possible 261 
overlap of reverse primer with the probe due to them only being separated by just one 262 
base. We substituted the biotinylated ITS 312R primer in place of the ITS 192R primer in the 263 
reactions to increase reverse primer-probe gap to 122 bases, however this was unsuccessful 264 
in preventing false positives occurring (Figure 2a). The ITS LF-RPA amplification products 265 
were purified and run on agarose gel to visualise any non-specific DNA products that might 266 
be causing the anomaly. It was evident that additional non-specific bands slightly smaller 267 
A B 
1     2     3    4    5    6  1     2  
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A B
← Control line
← Test line
than the target DNA bands were present in all lanes including the negative control, 268 
suggesting possible primer-dimer or primer-probe dimer products (Figure 2b). To try and 269 
reduce the possible primer-probe artefacts the addition of Betaine to the reactions was 270 
trialled. It was found that with the addition of 7.5µl of Betaine one of the primer pairs, ITS 271 
70F/ITS 312R, with an amplicon size of 242 bases did not produce false positives (Figure 3). 272 
This primer pair was used in all further ITS LF-RPA parameter-testing assays. 273 
 274 
 275 
 276 
 277 
 278 
 279 
 
 
 282 
Figure 2. A) Lateral flow results of the different ITS LF-RPA primer combinations plus a 283 
negative control that shows a false positive result. B) Gel images of the ITS LF-RPA reaction 284 
amplicons. A non-specific amplicon (the smaller band) can be seen in all the reactions and 285 
the negative control. The ladder in lane 1 is Hyperladder IV. 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
Figure 3. Positive and negative ITS LF-RPA reactions with the addition of 7.5µl of Betaine to 296 
the reactions. No false positives were obtained; A) using Milenia HybriDetect strips and B) 297 
PCRD Nucleic Acid Detector strips.  298 
 299 
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3.3.2 28S LF-RPA assays 300 
The 28S primer / probe combinations did not produce false positive results thus the 28S 301 
primer pair that gave the shortest amplicon of 294 bases (28S 353F/28S 647R) was used in 302 
all 28S LF-RPA parameter testing assays (Figure 4). 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
Figure 4. Positive and negative 28S LF-RPA reactions using the primer pair 353F and 647R.  311 
 312 
3.4 Performance of the Milenia vs. PCRD Nucleic Acid Detection Strips 313 
Both Milenia HybriDetect lateral flow strips and PCRD Nucleic Acid Detection strips were 314 
used for detection of ITS LF-RPA amplified products, to compare their performance (Figure 315 
5). We found that PCRD cassettes were more sensitive than the Milenia HybriDetect strips, 316 
able to detect ITS target DNA with one minute less RPA reaction incubation time than the 317 
Milenia HybriDetect strips (Figure 5). PCRD test lines consistently appeared more 318 
prominently than on the Milenia HybriDetect strips, which varied in intensity and were not 319 
uniform in clarity. Test lines also developed at a faster rate on PCRD strips. Due to their 320 
better performance, it was decided to use only PCRD cassettes for the remainder of the 321 
assays. 322 
 
 
 325 
 326 
 327 
 328 
 329 
 330 
+ve  
-ve  
mins 
A B 
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Figure 5. PCRD cassettes (A) gave more consistent results and were more sensitive able to 331 
detect DNA amplification after 8 mins of reaction time, whereas the limit of reaction time 332 
for the Milenia HybriDetect strips (B) was 9 minutes. NC = negative control 333 
 334 
3.5 LF-RPA ITS and 28S temperature and time parameter testing 335 
3.5.1 LF-RPA reaction temperature testing 336 
A positive signal was detectable at incubation temperatures between 30-45°C and 25-45°C 337 
for the ITS and 28S assays respectively, with the strongest signals occurring at 40°C and 338 
45°C, and no signal detected at 50°C (Supplementary File Figures 6+7). 339 
 340 
3.5.2 LF-RPA reaction time testing 341 
A positive signal could be detected with a limit of eight and six minute RPA reaction 342 
incubation time for the ITS and 28S assays respectively (Supplementary File Figures 8+9). 343 
 344 
3.6 Sensitivity testing 345 
The ITS LF-RPA assay was tested on serial dilutions of S. mansoni genomic DNA. 346 
Unfortunately at lower concentrations inconsistent results were obtained from reactions on 347 
the same concentration of DNA and so the limit of detection could not be evaluated further.  348 
For the 28S LF-RPA assay consistent results were obtained from replicate reactions and the 349 
28S LF-RPA assay limit of sensitivity was 10pg of DNA (Supplementary File Figure 10). 350 
 351 
3.7 Analytical limit of Detection of the 28S LF-RPA assay 352 
The analytical lower limit of detection for the 28S LF-RPA assay was 102 copies of DNA 353 
(Supplementary File Figure 11). 354 
 355 
3.8 Specificity with other important schistosome species 356 
The ITS LF-RPA assay proved to be not specific to S. mansoni and was also able to amplify S. 357 
haematobium and S. bovis DNA (Supplementary File Figure 12A) whereas the 28S LF-RPA 358 
assay proved to be more specific to S. mansoni but was still able to amplify S. haematobium 359 
and S. bovis DNA but at a lower sensitivity and with faint detection lines observed on the 360 
PCRD strips (Supplementary File Figure 12B).  361 
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4. Discussion 362 
A diagnostic test that is both sensitive and specific is of paramount importance to 363 
successfully monitor schistosomiasis transmission, particularly in low endemic areas. 364 
Inaccuracies in prevalence data due to lack of sensitivity of diagnostics could lead to a 365 
premature reduction/withdrawal of MDA, leading to a rapid resurgence of transmission and 366 
disease. Alternatively over-prescription of the drugs caused by a lack of diagnostic specificity 367 
causes wastage of medicine, insufficient supply of PZQ, systematic non-compliance and 368 
potentially could lead to the development of PZQ resistance. Ultimately this will prevent 369 
WHO elimination targets from being reached [5]. 370 
 Molecular diagnostics are the gold standard for several pathogens due to their 371 
greater specificity and sensitivity. However PCR based methods although sensitive, are 372 
expensive, difficult to use in low resource settings and experience slow turnaround times 373 
[16-18]. RPA is an alternative DNA-based method and overcomes several of the obstacles 374 
encountered by traditional DNA-based diagnostics [33-35]. RPA also demonstrates 375 
performance characteristics particularly suiting it to PON use. RPA reactions can operate at 376 
temperatures as low as 25 °C, albeit slower, so DNA amplification can be achieved using 377 
ambient temperature, body heat, room temperature or low power/ battery powered 378 
incubators, making the assay highly feasible in low resource settings where a reliable mains 379 
power supply may not be available [36]. This together with the LF detection system is simple 380 
to use and requires little in the way of training with results easily interpreted by untrained 381 
personnel. It is quick to turnaround with results available in less than 30 minutes after 382 
incubation initiation [36,37], which is particularly advantageous over existing isothermal 383 
systems such as Loop Mediated Isothermal Amplification (LAMP) that needs higher 384 
temperatures of 64°C for 90 mins [38]. Here, using the existing TwistDx platform, RPA has 385 
also been combined with the LF-RPA DNA amplification and detection system to detect S. 386 
mansoni DNA, which could be further optimised for the PON molecular diagnosis of human 387 
S. mansoni infections.  388 
Two DNA targets, the ribosomal ITS and 28S regions, were tested for their RPA 389 
performance with different primer and probe combinations. All primer pairs produced 390 
promising results with correct amplicon size amplification, however the ITS LF-RPA assays 391 
consistently produced false positive results probably due to some primer/probe secondary 392 
structure or hairpins possibly causing non-specific amplification creating false positive 393 
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results. These non-specific products could be visualised by gel electrophoresis of the ITS LF-394 
RPA reactions (Figure 2B). False positives were controlled with the addition of Betaine, 395 
which is often used in nucleic acid amplification to prevent secondary structures such as 396 
hairpins from forming, particularly where there is a high GC content [39]. With the addition 397 
of Betaine the ITS LF-RPA assay worked at a low temperature of 30°C with an eight-minute 398 
reaction time. The 28S LF-RPA assay proved more robust with no false positive reactions and 399 
the assay could be performed at lower temperatures (25°C) and with a shorter reaction 400 
time of six minutes.  401 
The primer pair used for the 28S LF-RPA assay (28S 353F/28S 647R), generated an 402 
amplicon of 295bp, longer than that recommended for RPA (<200bp) and had a slightly 403 
higher than recommended GC content (49.8% compared to 43.5% ITS). Longer amplicons 404 
generate a larger proportion of DNA artefacts such as hairpins and primer-dimers, due to 405 
the relatively faster replication of the shorter ‘noise’ fragments, and thus reduces 406 
sensitivity. In theory then the ITS assays (127 bp) would be predicted to outperform the 28S 407 
assays; however the 28S assays showed greater performance and reliability. These results 408 
highlight the importance of multiple primer and probe screening to develop optimal and 409 
robust RPA assays. 410 
The sensitivity of the ITS LF-RPA assays could not be assessed due to inconsistent 411 
results with low DNA concentrations probably due to inhibition caused by the Betaine in the 412 
reactions. The 28S LF-RPA had a limit of detection of 10pg of genomic DNA and 102 DNA 413 
copies, which was not as sensitive as previous studies where LF-RPA assays were able to 414 
detect down to 100fg of DNA for S. haematobium [22], and 5fg for S. japonicum [21]. 415 
Additionally, Pontes et al (2002) [18] were able to detect down to 1fg of pure S. mansoni 416 
DNA using PCR. However, all of these studies targeted highly repetitive elements within the 417 
genome, which have a higher copy number than the regions tested here, and thus could 418 
explain why the targeted regions showed lower sensitivity. Sandoval et al (2006) [40] found 419 
that a 28S PCR was able to detect down to 1pg of DNA, but that the sensitivity of the genus-420 
specific 28S region varied significantly depending on which primer pair was used. Sandoval 421 
et al (2006) [40] also reported the ITS region to be much less sensitive at detecting 422 
schistosome DNA than the 28S region when using PCR. However, an LF-RPA on the ITS1 423 
region of Fasciola hepatica was able to detect down to 1pg/µl in stool samples [41]. 424 
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Designing and testing alternative 28S and ITS primer and probe combinations and/or other 425 
DNA regions could therefore improve sensitivity, and should be investigated further [42,43]. 426 
LF-RPA amplification detection was trialled both using the PCRD nucleic acid 427 
detectors and the Milenia HybriDetect lateral flow dipsticks. The PCRD cassettes were more 428 
user friendly and the PCRD test bands were more uniform, easier to read, and developed 429 
more rapidly than the Milenia HybriDetect strips. According to the manufacturers, PCRD 430 
cassettes have a detection limit of 0.001µg/ml DNA. In this study PCRD did demonstrate a 431 
higher sensitivity: able to detect amplification products after shorter RPA assay incubation 432 
times than the Milenia HybriDetect strips. This could make PCRD a preferable detection tool 433 
in low intensity infections. 434 
The assays were shown to not be specific to S. mansoni but had some cross reactivity 435 
to S. haematobium and S. bovis. This offers both advantages in terms of being able to detect 436 
multiple schistosome species but also disadvantages in terms of specificity to S. mansoni. 437 
The cross-reactivity of the assay was not tested on negative control clinical samples or other 438 
pathogens that can also be found within stool samples and this will need to be done to 439 
evaluate clinical specificity. However, the compatibility of the primers to other organisms 440 
was checked using the NCBI blast tool with compatibility only shown with other non-441 
parasitic organisms. The assay’s utility will depend on what the diagnostic requirements are 442 
for the assays and if specificity is a priority. Other more species-specific DNA targets can be 443 
trialled in future work to improve specificity.   444 
This preliminary study offers a basis on which to conduct further RPA research and 445 
development with an aim to develop species-specific RPA assays to enable rapid field 446 
identification of different and multiple species involved in schistosomiasis infections. With 447 
further optimisation and validation the LF-RPA assays may prove to be a feasible diagnostic 448 
test for S. mansoni infection bringing PCR level sensitivity to the PON settings. Further 449 
development is needed to investigate different target DNA regions and primer/probe 450 
combinations to improve sensitivity and specificity. Field evaluation is also required to 451 
investigate the reliability of the targeted amplification of free schistosome DNA excreted in 452 
different types of clinical samples e.g. saliva, urine and plasma, as a by-product of the 453 
infection, together with the DNA that can be obtained from the excreted S. mansoni eggs in 454 
faecal samples [44].  455 
 In conclusion, the 28S LF-RPA assay developed here has high potential as a PON 456 
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diagnostic test for S. mansoni infections. It requires little in the way of equipment and 457 
technical support and results are quick to obtain and easy to interpret enhancing its 458 
suitability as a PON diagnostic test for individual patient management and disease 459 
mapping/surveillance as part of schistosomiasis control programmes [45,46].  460 
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